Wealthfront Advisers LLC Acquires Shares of 249,605 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Wealthfront Advisers LLC acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 249,605 shares of the company’s stock, valued at approximately $9,268,000.

Several other large investors have also modified their holdings of the stock. Pacer Advisors Inc. raised its stake in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp raised its stake in shares of Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after purchasing an additional 14,015 shares during the last quarter. Portolan Capital Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 201.1% during the third quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock worth $15,906,000 after purchasing an additional 218,901 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Amphastar Pharmaceuticals by 4.8% during the fourth quarter. Nordea Investment Management AB now owns 279,714 shares of the company’s stock worth $10,386,000 after purchasing an additional 12,851 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMPH. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company.

Amphastar Pharmaceuticals Trading Down 3.8 %

NASDAQ:AMPH opened at $26.28 on Thursday. The stock has a fifty day moving average price of $33.13 and a two-hundred day moving average price of $41.55. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of 8.76, a PEG ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 1 year low of $26.22 and a 1 year high of $53.96.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.